Sato Clinic

Chiba, Japan

Sato Clinic

Chiba, Japan
SEARCH FILTERS
Time filter
Source Type

Saito J.,Keio University | Saito J.,Inagi Municipal Hospital | Imamura Y.,Kogakuin University | Itoh J.,Itoh Co. | And 11 more authors.
Anticancer Research | Year: 2010

Background/Aim: We reported that endogenous urinary 3-hydroxyproline (3-Hyp) is useful for cancer screening because cancer invasion involves the destruction of basement membrane. A simple and sensitive assay is desired. Patients and Methods: An ELISA method using a specific antibody against a synthetic peptide of 10 amino acids including 3-Hyp corresponding to the amino acid sequences of collagen type IV alpha chain was applied to urine samples from 180 healthy controls and 22 cancer patients. Results: The values in controls were 2.44±1.90 (SD) mg peptide/g creatinine for 52 men and 2.87±2.01 for 128 women, while the values in 22 cancer patients were very low at 0.110±0.137 (p<0.001). Discussion: The discrepancy in the data between our previous and present studies is based on the difference of targets measured. 3-Hyp-containing peptides in cancer patients might be destroyed by the elevated peptidase levels found in these patients. Conclusion: This ELISA assay may be useful for cancer screening.


Shigematsu E.,Yokohama City University | Yamakawa T.,Yokohama City University | Taguri M.,Yokohama City University | Morita S.,Yokohama City University | And 7 more authors.
Journal of Atherosclerosis and Thrombosis | Year: 2012

Aim: The combination of ezetimibe and a statin provides greater LDL-C reduction by inhibiting both intestinal cholesterol absorption and endogenous production of cholesterol. The present study was designed to examine the influence of ageing, gender, BMI, levels of LDL-C, and HbA1c on the response to ezetimibe add-on therapy. Methods: Patients who had been taking a statin for >3 months at the usual dose and whose LDL-C was >120 mg/dL were eligible for this study. Patients were assigned to receive add-on ezetimibe at 10 mg once daily for 12 weeks. Results: Adding ezetimibe to basal statin therapy resulted in a further 15.0% reduction of TC, 20.5% reduction of LDL-C, and 19.7% reduction of non-HDL-C. The change in TC was significantly greater in males than in females. The change in TG was significantly greater in patients with a baseline TG level ≥150 mg/dL. Multivariate regression analysis showed that male sex and LDL-C ≥140 mg/dL were independent predictors of TC reduction after adjustment for age, BMI, and HbA1c. A baseline TG ≥150 mg/dL was also an independent predictor of TG reduction. Conclusion: Addition of ezetimibe to ongoing statin therapy was effective in patients with type 2 diabetes. Male sex and baseline LDL-C levels are independent predictors of marked TC reduction by ezetimibe treatment.


Hiraga M.,Kirishima Medical Center | Ikeda K.,Chiba University | Shigeta K.,Kirishima Medical Center | Sato A.,Sato Clinic | And 3 more authors.
Modern Rheumatology | Year: 2015

Introduction. Assessment of synovitis in the metatarsophalangeal (MTP) joints with ultrasound has been shown to improve the accuracy of assessment of rheumatoid arthritis (RA). However, the presence of intraarticular low-echoic synovial area (LESA) in the MTP joints in healthy subjects complicates the sonographic assessment of these joints. Method. Healthy subjects with no arthritic symptoms in their MTP joints were recruited. All subjects completed a questionnaire and underwent physical examination and sonographic assessment. LESAs in the dorsal aspect of all MTP joints were measured in the longitudinal view. Results. One thousand non-arthritic MTP joints in 100 healthy subjects (female 73, mean age 41.0 years old) were evaluated. Measurable LESAs were identified in all joints assessed. Mean length of LESA in each of the 1st - 5th MTP joints was 17.8, 13.9, 11.9, 10.6, and 9.2 mm, respectively, whereas mean thickness was 2.4, 2.4, 1.8, 1.2, and 0.8 mm, respectively. Multivariate linear regression models identified the difference between 1st and 5th MTP joints as the most independently influential factor on the measurement of LESA. Conclusions. Our data provide the normal reference values for the measurements of LESA in Japanese, which should be taken into consideration when the synovitis in MTP joints is evaluated with ultrasound. © 2014 Japan College of Rheumatology.


Horie A.,Diabetes Center | Tokuyama Y.,Kashiwado Hospital | Ishizuka T.,Sato Clinic | Suzuki Y.,Asahi General Hospital | And 5 more authors.
Hormone and Metabolic Research | Year: 2014

The aim of the present study was to determine whether the dipeptidyl peptidase (DPP)-4 inhibitor could repair pancreatic β-cell dysfunction and insulin resistance. Ten subjects with type 2 diabetes who had never received DPP-4 inhibitor treatment were enrolled in the study. Just before and 3 months after twice-daily administration of vildagliptin (50mg tablets), insulin secretion and insulin sensitivity were estimated using 2-compartment model analysis of C-peptide kinetics and insulin-modified minimal model parameters, respectively. The first-phase insulin secretion (CS1) was determined as the sum of the C-peptide secretion rate (CSR) from 0 to 5min (normal range 6.8-18.5ng/ml/min). The whole-body insulin sensitivity index (SI) was calculated using a minimal model software program (normal range 2.6-7.6×10-4/min/μU/ml). After vildagliptin treatment, reductions in mean (±SE) HbA1c were noted (43.28±1.53 vs. 40.98±1.77mmol/mol; p=0.019). Vildagliptin treatment increased the area under the curve for the C peptide reactivity (CPR) (AUCCPR; 26.66±5.15 vs. 33.02±6.12ng/ml·20min; p=0.003) and CS1 (0.80±0.20 vs. 1.35±0.38ng/ml/min; p=0.037) in response to an intravenous glucose load. Vildagliptin treatment significantly increased SI (0.46±0.27 vs. 1.21±0.48×10-4/min/μU/ml; p=0.037). The long-term administration of vildagliptin improved CS1 and Si suggesting that this drug has the capacity to repair impairments in pancreatic β-cell function and insulin resistance in type 2 diabetes. © Georg Thieme Verlag KG Stuttgart New York.


PubMed | Asahi General Hospital, The Diabetes Center, Sato Clinic and Kashiwado Hospital
Type: Journal Article | Journal: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme | Year: 2014

The aim of the present study was to determine whether the dipeptidyl peptidase (DPP)-4 inhibitor could repair pancreatic -cell dysfunction and insulin resistance. Ten subjects with type 2 diabetes who had never received DPP-4 inhibitor treatment were enrolled in the study. Just before and 3 months after twice-daily administration of vildagliptin (50mg tablets), insulin secretion and insulin sensitivity were estimated using 2-compartment model analysis of C-peptide kinetics and insulin-modified minimal model parameters, respectively. The first-phase insulin secretion (CS1) was determined as the sum of the C-peptide secretion rate (CSR) from 0 to 5min (normal range 6.8-18.5ng/ml/min). The whole-body insulin sensitivity index (SI) was calculated using a minimal model software program (normal range 2.6-7.610(-4)/min/U/ml). After vildagliptin treatment, reductions in mean (SE) HbA1c were noted (43.281.53 vs. 40.981.77mmol/mol; p=0.019). Vildagliptin treatment increased the area under the curve for the C peptide reactivity (CPR) (AUCCPR; 26.665.15 vs. 33.026.12ng/ml20min; p=0.003) and CS1 (0.800.20 vs. 1.350.38ng/ml/min; p=0.037) in response to an intravenous glucose load. -Vildagliptin treatment significantly increased SI (0.460.27 vs. 1.210.4810(-4)/min/U/ml; p=0.037). The long-term administration of vildagliptin improved CS1 and Si suggesting that this drug has the capacity to repair impairments in pancreatic -cell function and insulin resistance in type 2 diabetes.


Tomizawa M.,National Hospital Organization Shimoshizu Hospital | Kawanabe Y.,Sato Clinic | Shinozaki F.,National Hospital Organization Shimoshizu Hospital | Sato S.,Sato Clinic | And 4 more authors.
Experimental and Therapeutic Medicine | Year: 2014

In the present study, the threshold values of laboratory data for the diagnosis of non-alcoholic fatty liver disease (NAFLD) were investigated. The study enrolled patients who had undergone abdominal ultrasound (US) between April 2013 and August 2013, and for whom laboratory data were available on the same day. NAFLD was diagnosed following observations of a bright liver or hepatorenal echo contrast on the abdominal US scans. Patients were excluded from the study if they had liver diseases or had been prescribed prednisolone or methotrexate. Receiver operating characteristic curves, the Wilcoxon signed-rank test and Fisher's exact probability test were used for data analysis. In total, 80 NAFLD and 94 non-NAFLD patients were enrolled in the study. The threshold levels of alanine aminotransferase (ALT) and triglyceride (TG) for the diagnosis of NAFLD were 19.0 IU/l and 101 mg/dl, respectively. Patients were divided into two groups according to the levels of ALT and TG. Those with ALT levels of >19 IU/l and TG levels of >101 mg/dl were defined as the positive group, while the remaining patients were classified as the negative group. The specificity and positive predictive value using the combined threshold levels of ALT >19 IU/l and TG >101 mg/dl were 80.9 and 75.0%, respectively. Therefore, the results indicated that ALT levels of >19 IU/l or TG levels of >101 mg/dl were useful markers for the screening of NAFLD. However, NAFLD was more strongly suspected in patients with ALT levels of >19 IU/l and TG levels of >101 mg/dl.


PubMed | National Hospital Organization Shimoshizu Hospital and Sato Clinic
Type: Journal Article | Journal: Experimental and therapeutic medicine | Year: 2014

In the present study, the threshold values of laboratory data for the diagnosis of non-alcoholic fatty liver disease (NAFLD) were investigated. The study enrolled patients who had undergone abdominal ultrasound (US) between April 2013 and August 2013, and for whom laboratory data were available on the same day. NAFLD was diagnosed following observations of a bright liver or hepatorenal echo contrast on the abdominal US scans. Patients were excluded from the study if they had liver diseases or had been prescribed prednisolone or methotrexate. Receiver operating characteristic curves, the Wilcoxon signed-rank test and Fishers exact probability test were used for data analysis. In total, 80 NAFLD and 94 non-NAFLD patients were enrolled in the study. The threshold levels of alanine aminotransferase (ALT) and triglyceride (TG) for the diagnosis of NAFLD were 19.0 IU/l and 101 mg/dl, respectively. Patients were divided into two groups according to the levels of ALT and TG. Those with ALT levels of >19 IU/l and TG levels of >101 mg/dl were defined as the positive group, while the remaining patients were classified as the negative group. The specificity and positive predictive value using the combined threshold levels of ALT >19 IU/l and TG >101 mg/dl were 80.9 and 75.0%, respectively. Therefore, the results indicated that ALT levels of >19 IU/l or TG levels of >101 mg/dl were useful markers for the screening of NAFLD. However, NAFLD was more strongly suspected in patients with ALT levels of >19 IU/l and TG levels of >101 mg/dl.


Aikawa T.,Aikawa Internal Medicine Hospital | Sugiyama H.,Tsukuba Memorial Hospital | Soeda A.,Tsukuba Memorial Hospital | Ikezawa K.,Tsukuba Memorial Hospital | And 4 more authors.
Acta Hepatologica Japonica | Year: 2014

To examine recent trends of acute infection with hepatitis B virus (HBV) in Mito, located in a non-Metropolitan area of Japan, serum samples obtained from 17 patients with acute hepatitis B (AHB) and 243 patients with chronic HBV infection during 2001-2013 were subjected to HBV genotyping. HBV genotype A (GtA) was detected in 3 (1%), GtB in 64 (26%) and GtC in 174 (72%) of patients with chronic HBV infection, while GtA was most prevalent (47%) among the AHB patients. Of note, GtA was found significantly more frequently in AHB patients during 2008-2013 than in those during 2001-2007 (64% vs. 17%, p<0.0001). These increasing trends of GtA HBV infection via sexual transmission emphasize the necessity of preventive education and measures. © 2014 The Japan Society of Hepatology.

Loading Sato Clinic collaborators
Loading Sato Clinic collaborators